View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
September 8, 2020updated 01 Oct 2020 6:47am

Destiny Pharma and SporeGen to develop preventive Covid-19 therapy

UK-based biotechnology firm Destiny Pharma has partnered with SporeGen to jointly develop the latter's SPOR-COV product candidate as a preventive treatment against Covid-19.

UK-based biotechnology firm Destiny Pharma has partnered with SporeGen to jointly develop the latter’s SPOR-COV product candidate as a preventive treatment against Covid-19.

Free Whitepaper

Secure the cell therapy supply chain from bench to bedside

The development of cell therapies is changing healthcare, delivering new hope to thousands of patients around the world. The vein-to-vein workflow for these therapies, however, is not without challenges, many of which will increase as we scale up to treat more patients. Download this free guide from Cytiva to learn more about the challenges and risks associated with the cryogenic supply chain for cell therapies, and how supply chain disruptions can best be mitigated.
by Cytiva Thematic

By clicking the Download Free Whitepaper button, you accept the terms and conditions and acknowledge that your data will be used as described in the Cytiva Thematic privacy policy

By downloading this Whitepaper, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

As part of a collaboration agreement, the companies will share any costs and commercial returns from the product. The aim is to complete a pre-clinical programme and be ready to launch the first human clinical trials within 18 months.

Destiny Pharma will combine its pre-clinical and clinical drug development expertise with SporeGen’s understanding of Bacillus bacterial spores to progress SPOR‑COV.

SPOR‑COV, made up of a Bacillus bacteria formulation, is administered as a nasal spray. In preclinical models of influenza virus, the product provided complete protection.

Intended to leverage the innate immune system to develop Covid-19 protection a few days after dosing, SPOR-COV could help significantly reduce infection rates and transmission.

The companies hope to make the product available globally as a cost-effective measure against Covid-19, new Covid strains and other respiratory viral infections.

Destiny Pharma CEO Neil Clark said: “Destiny Pharma is committed to building a novel pipeline targeted at preventing infections and is very pleased to now be working with partners on the SPOR-COV project alongside our existing in-house XF platform.

“The ongoing coronavirus pandemic has highlighted powerfully the need for innovation in developing new treatments to prevent and manage both viral and bacterial infections and Destiny Pharma remains committed to developing cost-effective products that meet this medical need.”

Destiny Pharma and SporeGen received an £800,000 Innovate UK grant to support the £1m cost of the initial SPOR-COV programme.

The preclinical efficacy work will take place in alliance with professor Aras Kadioglu, at the University of Liverpool.

Meanwhile, HURO will perform manufacturing and formulation development activities, a manufacturer of bacterial product formulations based in Vietnam.

Related Companies

Free Report

Navigate your business through the ‘new normal’

COVID-19 continues to dominate headlines the world over. It has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities.  Faced with an explosion of conflicting information on how to plan and implement successful recovery strategies, decision-makers are in dire need of a single, reliable source of intelligence.   GlobalData’s COVID-19 Executive Briefing gives you access to unparalleled data and insights to successfully navigate the uncertain road to recovery across the world’s largest industries. Understand every aspect of this disruptive theme by delving into: 
  •  COVID-19 infection update, with statistics on the spread, testing by country, as well as the latest data on vaccines and therapeutic developments 
  • Economic impact overview, covering stock market indices, GDP, unemployment rates, policy responses & GlobalData’s economic recovery scorecards 
  • Sector developments, with access to sector insight summaries, cross-sector indices and the leaders and laggards in each industry vertical 
Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today. 
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy